
A Potentially Disruptive Technology
Galimedix Therapeutics is developing two unique small molecules GAL-101 and GAL-201 specifically to block a key underlying step in neurodegeneration: formation of toxic oligomers of amyloid beta (Aβ). These toxic Aβ oligomers have emerged as the central cause in neurodegeneration, as further bolstered by recent results from Phase 3 clinical trials with Aducanumab reported by Biogen. GAL-101 and GAL-201 are small molecules designed to prevent and clear precisely such Aβ oligomers. GAL-101 has shown compelling efficacy results in animal studies as an eye drop treatment for glaucoma and dry AMD, and as an oral version for Alzheimer’s disease, demonstrating strong potential not only to slow or stop the degeneration, but to also restore lost neuronal function.
Our Technology